Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-04-10

AUTHORS

Masakazu Haneda, Takashi Kadowaki, Hiroshi Ito, Kazuyo Sasaki, Sonoe Hiraide, Manabu Ishii, Miyuki Matsukawa, Makoto Ueno

ABSTRACT

IntroductionTeneligliptin is a novel oral dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus (T2DM). Safety and efficacy of teneligliptin have been demonstrated in clinical studies; however, data supporting its use in patients with moderate or severe renal impairment are limited. This interim analysis of a post-marketing surveillance of teneligliptin, exploRing the long-term efficacy and safety included cardiovascUlar events in patients with type 2 diaBetes treated bY teneligliptin in the real-world (RUBY), aims to verify the long-term safety and efficacy of teneligliptin in Japanese patients with T2DM and impaired renal function.MethodsFor this analysis, we used the data from case report forms of the RUBY surveillance between May 2013 and June 2017. The patients were classified into G1–G5 stages of chronic kidney disease according to estimated glomerular filtration rate (eGFR) at initiation of teneligliptin treatment. Safety and efficacy were evaluated in these subgroups. Patients on dialysis were also assessed. Safety was assessed from adverse drug reactions (ADRs). Glycemic control was evaluated up to 2 years after teneligliptin initiation.ResultsA total of 11,677 patients were enrolled in the surveillance and 11,425 patient case-report forms were collected for the interim analysis. The incidence of ADRs in each subgroup was 2.98–6.98% of patients, with no differences in the ADR profile (including hypoglycemia and renal function ADRs) between subgroups. At 1 and 2 years after starting teneligliptin, the least-squares mean change in HbA1c adjusted to the baseline was − 0.68 to − 0.85% and − 0.71 to − 0.85% across the eGFR groups, respectively. Treatment with teneligliptin in patients on dialysis reduced or tended to reduce glycated albumin levels [− 2.29%, (p < 0.001) after 1 year; − 1.64%, (p = 0.064) after 2 years].ConclusionsDuring long-term treatment, teneligliptin was generally well tolerated in patients with any stage of renal impairment from normal to end-stage renal disease, including those on dialysis, and improved glycemic control.Trial Registration NumberJapic CTI-153047.FundingMitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co, Ltd. More... »

PAGES

1083-1097

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-018-0416-2

DOI

http://dx.doi.org/10.1007/s13300-018-0416-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1103202152

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29637459


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Medical Corporation Kyousoukai, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Medicine, Asahikawa Medical University, Hokkaido, Japan", 
            "Medical Corporation Kyousoukai, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haneda", 
        "givenName": "Masakazu", 
        "id": "sg:person.01342044323.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342044323.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kadowaki", 
        "givenName": "Takashi", 
        "id": "sg:person.01353472360.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353472360.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.261356.5", 
          "name": [
            "Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ito", 
        "givenName": "Hiroshi", 
        "id": "sg:person.013440705734.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013440705734.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.418306.8", 
          "name": [
            "Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sasaki", 
        "givenName": "Kazuyo", 
        "id": "sg:person.01335361505.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335361505.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.418306.8", 
          "name": [
            "Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hiraide", 
        "givenName": "Sonoe", 
        "id": "sg:person.016326663135.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016326663135.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.418306.8", 
          "name": [
            "Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ishii", 
        "givenName": "Manabu", 
        "id": "sg:person.010341122554.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010341122554.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.418306.8", 
          "name": [
            "Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsukawa", 
        "givenName": "Miyuki", 
        "id": "sg:person.014325424431.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014325424431.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.418306.8", 
          "name": [
            "Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ueno", 
        "givenName": "Makoto", 
        "id": "sg:person.013420536353.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013420536353.65"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nrneph.2015.173", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005578989", 
          "https://doi.org/10.1038/nrneph.2015.173"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-014-3372-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005357264", 
          "https://doi.org/10.1007/s00125-014-3372-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00592-012-0442-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040974491", 
          "https://doi.org/10.1007/s00592-012-0442-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-014-3460-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015538250", 
          "https://doi.org/10.1007/s00125-014-3460-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrdp.2015.18", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029591413", 
          "https://doi.org/10.1038/nrdp.2015.18"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11255-013-0552-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048998386", 
          "https://doi.org/10.1007/s11255-013-0552-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s41100-017-0097-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083917214", 
          "https://doi.org/10.1186/s41100-017-0097-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-016-0189-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008454817", 
          "https://doi.org/10.1007/s13300-016-0189-4"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-04-10", 
    "datePublishedReg": "2018-04-10", 
    "description": "IntroductionTeneligliptin is a novel oral dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus (T2DM). Safety and efficacy of teneligliptin have been demonstrated in clinical studies; however, data supporting its use in patients with moderate or severe renal impairment are limited. This interim analysis of a post-marketing surveillance of teneligliptin, exploRing the long-term efficacy and safety included cardiovascUlar events in patients with type 2 diaBetes treated bY teneligliptin in the real-world (RUBY), aims to verify the long-term safety and efficacy of teneligliptin in Japanese patients with T2DM and impaired renal function.MethodsFor this analysis, we used the data from case report forms of the RUBY surveillance between May 2013 and June 2017. The patients were classified into G1\u2013G5 stages of chronic kidney disease according to estimated glomerular filtration rate (eGFR) at initiation of teneligliptin treatment. Safety and efficacy were evaluated in these subgroups. Patients on dialysis were also assessed. Safety was assessed from adverse drug reactions (ADRs). Glycemic control was evaluated up to 2\u00a0years after teneligliptin initiation.ResultsA total of 11,677 patients were enrolled in the surveillance and 11,425 patient case-report forms were collected for the interim analysis. The incidence of ADRs in each subgroup was 2.98\u20136.98% of patients, with no differences in the ADR profile (including hypoglycemia and renal function ADRs) between subgroups. At 1 and 2\u00a0years after starting teneligliptin, the least-squares mean change in HbA1c adjusted to the baseline was \u2212\u00a00.68 to \u2212\u00a00.85% and \u2212\u00a00.71 to \u2212\u00a00.85% across the eGFR groups, respectively. Treatment with teneligliptin in patients on dialysis reduced or tended to reduce glycated albumin levels [\u2212\u00a02.29%, (p\u2009<\u20090.001) after 1\u00a0year; \u2212\u00a01.64%, (p\u2009=\u20090.064) after 2\u00a0years].ConclusionsDuring long-term treatment, teneligliptin was generally well tolerated in patients with any stage of renal impairment from normal to end-stage renal disease, including those on dialysis, and improved glycemic control.Trial Registration NumberJapic CTI-153047.FundingMitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co, Ltd.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-018-0416-2", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "keywords": [
      "efficacy of teneligliptin", 
      "adverse drug reactions", 
      "case report forms", 
      "renal impairment", 
      "renal function", 
      "glycemic control", 
      "interim analysis", 
      "oral dipeptidyl peptidase-4 inhibitor", 
      "incidence of ADRs", 
      "patient case report forms", 
      "end-stage renal disease", 
      "dipeptidyl peptidase-4 inhibitors", 
      "type 2 diabetes mellitus", 
      "severe renal impairment", 
      "impaired renal function", 
      "chronic kidney disease", 
      "glomerular filtration rate", 
      "peptidase-4 inhibitors", 
      "long-term efficacy", 
      "type 2 diabetes", 
      "long-term treatment", 
      "long-term safety", 
      "post-marketing surveillance", 
      "teneligliptin treatment", 
      "cardiovascular events", 
      "post-market surveillance", 
      "diabetes mellitus", 
      "albumin levels", 
      "renal disease", 
      "kidney disease", 
      "ResultsA total", 
      "drug reactions", 
      "eGFR group", 
      "filtration rate", 
      "Japanese patients", 
      "clinical studies", 
      "patients", 
      "ADR profile", 
      "teneligliptin", 
      "type 2", 
      "report forms", 
      "efficacy", 
      "dialysis", 
      "mellitus", 
      "treatment", 
      "surveillance", 
      "subgroups", 
      "disease", 
      "impairment", 
      "safety", 
      "HbA1c", 
      "T2DM", 
      "diabetes", 
      "initiation", 
      "years", 
      "interim report", 
      "incidence", 
      "baseline", 
      "MethodsFor", 
      "total", 
      "control", 
      "inhibitors", 
      "report", 
      "group", 
      "stage", 
      "function", 
      "levels", 
      "data", 
      "differences", 
      "analysis", 
      "study", 
      "rate", 
      "events", 
      "profile", 
      "changes", 
      "use", 
      "form", 
      "reaction", 
      "CO", 
      "corporations"
    ], 
    "name": "Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance", 
    "pagination": "1083-1097", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1103202152"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-018-0416-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29637459"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-018-0416-2", 
      "https://app.dimensions.ai/details/publication/pub.1103202152"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:02", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_794.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-018-0416-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0416-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0416-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0416-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0416-2'


 

This table displays all metadata directly associated to this object as RDF triples.

232 TRIPLES      21 PREDICATES      113 URIs      97 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-018-0416-2 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N11ec20f68b3b43a6abb27121dabe5fb0
4 schema:citation sg:pub.10.1007/s00125-014-3372-z
5 sg:pub.10.1007/s00125-014-3460-0
6 sg:pub.10.1007/s00592-012-0442-x
7 sg:pub.10.1007/s11255-013-0552-6
8 sg:pub.10.1007/s13300-016-0189-4
9 sg:pub.10.1038/nrdp.2015.18
10 sg:pub.10.1038/nrneph.2015.173
11 sg:pub.10.1186/s41100-017-0097-8
12 schema:datePublished 2018-04-10
13 schema:datePublishedReg 2018-04-10
14 schema:description IntroductionTeneligliptin is a novel oral dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus (T2DM). Safety and efficacy of teneligliptin have been demonstrated in clinical studies; however, data supporting its use in patients with moderate or severe renal impairment are limited. This interim analysis of a post-marketing surveillance of teneligliptin, exploRing the long-term efficacy and safety included cardiovascUlar events in patients with type 2 diaBetes treated bY teneligliptin in the real-world (RUBY), aims to verify the long-term safety and efficacy of teneligliptin in Japanese patients with T2DM and impaired renal function.MethodsFor this analysis, we used the data from case report forms of the RUBY surveillance between May 2013 and June 2017. The patients were classified into G1–G5 stages of chronic kidney disease according to estimated glomerular filtration rate (eGFR) at initiation of teneligliptin treatment. Safety and efficacy were evaluated in these subgroups. Patients on dialysis were also assessed. Safety was assessed from adverse drug reactions (ADRs). Glycemic control was evaluated up to 2 years after teneligliptin initiation.ResultsA total of 11,677 patients were enrolled in the surveillance and 11,425 patient case-report forms were collected for the interim analysis. The incidence of ADRs in each subgroup was 2.98–6.98% of patients, with no differences in the ADR profile (including hypoglycemia and renal function ADRs) between subgroups. At 1 and 2 years after starting teneligliptin, the least-squares mean change in HbA1c adjusted to the baseline was − 0.68 to − 0.85% and − 0.71 to − 0.85% across the eGFR groups, respectively. Treatment with teneligliptin in patients on dialysis reduced or tended to reduce glycated albumin levels [− 2.29%, (p < 0.001) after 1 year; − 1.64%, (p = 0.064) after 2 years].ConclusionsDuring long-term treatment, teneligliptin was generally well tolerated in patients with any stage of renal impairment from normal to end-stage renal disease, including those on dialysis, and improved glycemic control.Trial Registration NumberJapic CTI-153047.FundingMitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co, Ltd.
15 schema:genre article
16 schema:isAccessibleForFree true
17 schema:isPartOf N8afa153d57c24f6a9dbb3d7716f8c691
18 Nb8c7950d8bcc47e7ba15e6a4119dea12
19 sg:journal.1044057
20 schema:keywords ADR profile
21 CO
22 HbA1c
23 Japanese patients
24 MethodsFor
25 ResultsA total
26 T2DM
27 adverse drug reactions
28 albumin levels
29 analysis
30 baseline
31 cardiovascular events
32 case report forms
33 changes
34 chronic kidney disease
35 clinical studies
36 control
37 corporations
38 data
39 diabetes
40 diabetes mellitus
41 dialysis
42 differences
43 dipeptidyl peptidase-4 inhibitors
44 disease
45 drug reactions
46 eGFR group
47 efficacy
48 efficacy of teneligliptin
49 end-stage renal disease
50 events
51 filtration rate
52 form
53 function
54 glomerular filtration rate
55 glycemic control
56 group
57 impaired renal function
58 impairment
59 incidence
60 incidence of ADRs
61 inhibitors
62 initiation
63 interim analysis
64 interim report
65 kidney disease
66 levels
67 long-term efficacy
68 long-term safety
69 long-term treatment
70 mellitus
71 oral dipeptidyl peptidase-4 inhibitor
72 patient case report forms
73 patients
74 peptidase-4 inhibitors
75 post-market surveillance
76 post-marketing surveillance
77 profile
78 rate
79 reaction
80 renal disease
81 renal function
82 renal impairment
83 report
84 report forms
85 safety
86 severe renal impairment
87 stage
88 study
89 subgroups
90 surveillance
91 teneligliptin
92 teneligliptin treatment
93 total
94 treatment
95 type 2
96 type 2 diabetes
97 type 2 diabetes mellitus
98 use
99 years
100 schema:name Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance
101 schema:pagination 1083-1097
102 schema:productId N4b527f25ae4746b098ab21e6c9d059e6
103 N7f7fde920c114ae09abc746665a5f7ab
104 Nd0868d86e81f4f93ab258f03461929bc
105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103202152
106 https://doi.org/10.1007/s13300-018-0416-2
107 schema:sdDatePublished 2022-09-02T16:02
108 schema:sdLicense https://scigraph.springernature.com/explorer/license/
109 schema:sdPublisher N389ab2bf1e8e490481bcae7678d2195b
110 schema:url https://doi.org/10.1007/s13300-018-0416-2
111 sgo:license sg:explorer/license/
112 sgo:sdDataset articles
113 rdf:type schema:ScholarlyArticle
114 N02946274d54049578a91e78d20a9a2f7 rdf:first sg:person.016326663135.44
115 rdf:rest N8bb8322aa3104f06baa8afe097df7f14
116 N11ec20f68b3b43a6abb27121dabe5fb0 rdf:first sg:person.01342044323.24
117 rdf:rest N7f88b05d14f94e6582e579c03ab5513a
118 N1cf790ea01ea46618926cd8a3a133bc9 rdf:first sg:person.013420536353.65
119 rdf:rest rdf:nil
120 N389ab2bf1e8e490481bcae7678d2195b schema:name Springer Nature - SN SciGraph project
121 rdf:type schema:Organization
122 N4b527f25ae4746b098ab21e6c9d059e6 schema:name doi
123 schema:value 10.1007/s13300-018-0416-2
124 rdf:type schema:PropertyValue
125 N7f7fde920c114ae09abc746665a5f7ab schema:name pubmed_id
126 schema:value 29637459
127 rdf:type schema:PropertyValue
128 N7f88b05d14f94e6582e579c03ab5513a rdf:first sg:person.01353472360.41
129 rdf:rest Nf125ae80cd284610be8bd4acb3786b22
130 N8afa153d57c24f6a9dbb3d7716f8c691 schema:issueNumber 3
131 rdf:type schema:PublicationIssue
132 N8bb8322aa3104f06baa8afe097df7f14 rdf:first sg:person.010341122554.91
133 rdf:rest N975f051fa2544a8c869f84166c32dc79
134 N92033e30d62446f79edcd699a466a5bd rdf:first sg:person.01335361505.82
135 rdf:rest N02946274d54049578a91e78d20a9a2f7
136 N975f051fa2544a8c869f84166c32dc79 rdf:first sg:person.014325424431.13
137 rdf:rest N1cf790ea01ea46618926cd8a3a133bc9
138 Nb8c7950d8bcc47e7ba15e6a4119dea12 schema:volumeNumber 9
139 rdf:type schema:PublicationVolume
140 Nd0868d86e81f4f93ab258f03461929bc schema:name dimensions_id
141 schema:value pub.1103202152
142 rdf:type schema:PropertyValue
143 Nf125ae80cd284610be8bd4acb3786b22 rdf:first sg:person.013440705734.23
144 rdf:rest N92033e30d62446f79edcd699a466a5bd
145 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
146 schema:name Medical and Health Sciences
147 rdf:type schema:DefinedTerm
148 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
149 schema:name Clinical Sciences
150 rdf:type schema:DefinedTerm
151 sg:journal.1044057 schema:issn 1869-6953
152 1869-6961
153 schema:name Diabetes Therapy
154 schema:publisher Springer Nature
155 rdf:type schema:Periodical
156 sg:person.010341122554.91 schema:affiliation grid-institutes:grid.418306.8
157 schema:familyName Ishii
158 schema:givenName Manabu
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010341122554.91
160 rdf:type schema:Person
161 sg:person.01335361505.82 schema:affiliation grid-institutes:grid.418306.8
162 schema:familyName Sasaki
163 schema:givenName Kazuyo
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335361505.82
165 rdf:type schema:Person
166 sg:person.01342044323.24 schema:affiliation grid-institutes:None
167 schema:familyName Haneda
168 schema:givenName Masakazu
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342044323.24
170 rdf:type schema:Person
171 sg:person.013420536353.65 schema:affiliation grid-institutes:grid.418306.8
172 schema:familyName Ueno
173 schema:givenName Makoto
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013420536353.65
175 rdf:type schema:Person
176 sg:person.013440705734.23 schema:affiliation grid-institutes:grid.261356.5
177 schema:familyName Ito
178 schema:givenName Hiroshi
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013440705734.23
180 rdf:type schema:Person
181 sg:person.01353472360.41 schema:affiliation grid-institutes:grid.26999.3d
182 schema:familyName Kadowaki
183 schema:givenName Takashi
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353472360.41
185 rdf:type schema:Person
186 sg:person.014325424431.13 schema:affiliation grid-institutes:grid.418306.8
187 schema:familyName Matsukawa
188 schema:givenName Miyuki
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014325424431.13
190 rdf:type schema:Person
191 sg:person.016326663135.44 schema:affiliation grid-institutes:grid.418306.8
192 schema:familyName Hiraide
193 schema:givenName Sonoe
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016326663135.44
195 rdf:type schema:Person
196 sg:pub.10.1007/s00125-014-3372-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1005357264
197 https://doi.org/10.1007/s00125-014-3372-z
198 rdf:type schema:CreativeWork
199 sg:pub.10.1007/s00125-014-3460-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015538250
200 https://doi.org/10.1007/s00125-014-3460-0
201 rdf:type schema:CreativeWork
202 sg:pub.10.1007/s00592-012-0442-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1040974491
203 https://doi.org/10.1007/s00592-012-0442-x
204 rdf:type schema:CreativeWork
205 sg:pub.10.1007/s11255-013-0552-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048998386
206 https://doi.org/10.1007/s11255-013-0552-6
207 rdf:type schema:CreativeWork
208 sg:pub.10.1007/s13300-016-0189-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008454817
209 https://doi.org/10.1007/s13300-016-0189-4
210 rdf:type schema:CreativeWork
211 sg:pub.10.1038/nrdp.2015.18 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029591413
212 https://doi.org/10.1038/nrdp.2015.18
213 rdf:type schema:CreativeWork
214 sg:pub.10.1038/nrneph.2015.173 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005578989
215 https://doi.org/10.1038/nrneph.2015.173
216 rdf:type schema:CreativeWork
217 sg:pub.10.1186/s41100-017-0097-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083917214
218 https://doi.org/10.1186/s41100-017-0097-8
219 rdf:type schema:CreativeWork
220 grid-institutes:None schema:alternateName Medical Corporation Kyousoukai, Osaka, Japan
221 schema:name Department of Medicine, Asahikawa Medical University, Hokkaido, Japan
222 Medical Corporation Kyousoukai, Osaka, Japan
223 rdf:type schema:Organization
224 grid-institutes:grid.261356.5 schema:alternateName Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
225 schema:name Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
226 rdf:type schema:Organization
227 grid-institutes:grid.26999.3d schema:alternateName Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
228 schema:name Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
229 rdf:type schema:Organization
230 grid-institutes:grid.418306.8 schema:alternateName Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan
231 schema:name Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan
232 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...